Brokerages forecast that Globus Medical Inc (NYSE:GMED) will post $0.43 earnings per share for the current quarter, Zacks reports. Three analysts have issued estimates for Globus Medical’s earnings. The highest EPS estimate is $0.44 and the lowest is $0.42. Globus Medical posted earnings of $0.39 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 10.3%. The company is scheduled to issue its next quarterly earnings report on Thursday, November 14th.

On average, analysts expect that Globus Medical will report full-year earnings of $1.71 per share for the current fiscal year, with EPS estimates ranging from $1.69 to $1.72. For the next year, analysts forecast that the company will post earnings of $1.90 per share, with EPS estimates ranging from $1.86 to $1.94. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Globus Medical.

Globus Medical (NYSE:GMED) last released its earnings results on Thursday, August 1st. The medical device company reported $0.41 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.41. The business had revenue of $150.55 million for the quarter, compared to analyst estimates of $184.93 million. Globus Medical had a net margin of 19.30% and a return on equity of 13.29%. Globus Medical’s revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.44 earnings per share.

Several research firms have weighed in on GMED. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 price target (up from $52.00) on shares of Globus Medical in a research note on Friday, August 2nd. Morgan Stanley set a $45.00 price target on shares of Globus Medical and gave the company a “hold” rating in a research note on Wednesday, June 5th. Wells Fargo & Co downgraded shares of Globus Medical from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $50.00 to $41.00 in a research note on Friday, May 24th. Finally, Zacks Investment Research raised shares of Globus Medical from a “sell” rating to a “hold” rating and set a $54.00 price target for the company in a research note on Tuesday, August 6th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $55.20.

GMED traded down $0.47 during midday trading on Wednesday, hitting $48.37. The company had a trading volume of 19,038 shares, compared to its average volume of 629,505. Globus Medical has a 52 week low of $38.01 and a 52 week high of $57.83. The stock has a market cap of $4.87 billion, a P/E ratio of 28.91, a price-to-earnings-growth ratio of 2.52 and a beta of 0.89. The stock’s 50 day simple moving average is $44.08.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. WINTON GROUP Ltd increased its position in shares of Globus Medical by 122.8% during the second quarter. WINTON GROUP Ltd now owns 11,756 shares of the medical device company’s stock worth $497,000 after acquiring an additional 6,480 shares in the last quarter. THB Asset Management bought a new stake in shares of Globus Medical during the first quarter worth about $215,000. Campbell & CO Investment Adviser LLC bought a new stake in shares of Globus Medical during the second quarter worth about $280,000. Virginia Retirement Systems ET AL increased its position in shares of Globus Medical by 9.0% during the first quarter. Virginia Retirement Systems ET AL now owns 39,900 shares of the medical device company’s stock worth $1,971,000 after acquiring an additional 3,300 shares in the last quarter. Finally, Retirement Systems of Alabama increased its position in shares of Globus Medical by 29.9% during the first quarter. Retirement Systems of Alabama now owns 285,420 shares of the medical device company’s stock worth $14,103,000 after acquiring an additional 65,688 shares in the last quarter. 69.61% of the stock is owned by hedge funds and other institutional investors.

About Globus Medical

Globus Medical, Inc, a medical device company, focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders. The company offers products that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches.

Featured Article: Municipal Bonds

Get a free copy of the Zacks research report on Globus Medical (GMED)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Globus Medical (NYSE:GMED)

Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.